These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12362748)

  • 1. [Ranking the efficacy of drugs--a question of "class"? It is difficult to determine equivalency of two different treatments].
    Liedholm H; Linné AB
    Lakartidningen; 2002 Sep; 99(36):3492-4, 3497-9, 3502. PubMed ID: 12362748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equivalence trials: methodologic analysis.
    Carneiro A
    Rev Port Cardiol; 2003 Sep; 22(9):1125-39. PubMed ID: 14655314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?
    Antman EM; Ferguson JJ
    Circulation; 2003 Nov; 108(21):2604-7. PubMed ID: 14638523
    [No Abstract]   [Full Text] [Related]  

  • 6. [Methodological and statistical aspects of equivalence and non inferiority trials].
    Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
    Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?
    Furberg CD; Psaty BM
    Circulation; 2003 Nov; 108(21):2608-10. PubMed ID: 14638524
    [No Abstract]   [Full Text] [Related]  

  • 8. [Class substitution as an instrument of efficiency in the supply of medicines: possibilities and limitations].
    de Smet PA; van der Kuy A; Bonsel GJ
    Ned Tijdschr Geneeskd; 2002 Mar; 146(12):553-7. PubMed ID: 11938577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinational medicines--ensuring drug quality in an era of global manufacturing.
    Okie S
    N Engl J Med; 2009 Aug; 361(8):737-40. PubMed ID: 19692686
    [No Abstract]   [Full Text] [Related]  

  • 10. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug class effects: definitions and practical applications.
    Soares I; Carneiro AV
    Rev Port Cardiol; 2002 Sep; 21(9):1031-42. PubMed ID: 12416274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Follow up studies as a condition for drug subsidizing].
    Kieler H; Ekbom A; Fored M; Montgomery SM; Wettermark B
    Lakartidningen; 2009 May 13-19; 106(20):1406-7. PubMed ID: 19585842
    [No Abstract]   [Full Text] [Related]  

  • 13. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged.
    Wehling M
    J Am Geriatr Soc; 2009 Mar; 57(3):560-1. PubMed ID: 19278399
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of Biopharmaceutics Classification System-based biowaivers.
    Cook JA; Davit BM; Polli JE
    Mol Pharm; 2010 Oct; 7(5):1539-44. PubMed ID: 20735084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are drugs within a class interchangeable?
    Furberg CD; Herrington DM; Psaty BM
    Lancet; 1999 Oct; 354(9185):1202-4. PubMed ID: 10513728
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy and adverse effect of drugs monitored by blood concentration].
    Echizen H
    Nihon Naika Gakkai Zasshi; 1992 Sep; 81(9):1547-9. PubMed ID: 1453078
    [No Abstract]   [Full Text] [Related]  

  • 18. Descriptive tools and analysis.
    Capellà D
    WHO Reg Publ Eur Ser; 1993; 45():55-78. PubMed ID: 8442851
    [No Abstract]   [Full Text] [Related]  

  • 19. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic drugs.
    Med Lett Drugs Ther; 1999 May; 41(1053):47-8. PubMed ID: 10368699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.